Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
STAMFORD, Conn., Sept. 02, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016, at 10:30 a.m. ET in New York.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
